Announcements Trials
Browse Landscape

Phase

Phase 3 17Phase 2 13Phase 1/2 12Phase 1 6Phase 4 3Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1

Conditions

Breast Neoplasms 2Solid Tumors 1

Interventions

Letrozole 5Tamoxifen 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Injections 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3trametinib 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Specimen Handling 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Oxaliplatin 2Medroxyprogesterone Acetate 2Leucovorin 2Lenalidomide 2Ipilimumab 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × ribociclib × 90 days × Clear all
NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Pfizer

Phase 4 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡